 CryoLife, Inc. NYSE: CRY CryoLife or the Company, a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, 100,000,000 aggregate principal amount of convertible senior notes due 2025 the Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended the Securities Act. CryoLife also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional 15,000,000 aggregate principal amount of the Notes. 